Antiangiogenic approaches for the treatment of advanced synovial sarcomas.

Current Opinion in Oncology
Khanh DoShivaani Kummar

Abstract

Synovial sarcomas are regarded as chemosensitive tumors compared to other types of soft tissue sarcomas, however, prognosis for advanced refractory disease remains poor. In light of the vascular nature of sarcomas, current molecularly targeted therapies aim at an antiangiogenic approach to management of this disease. Recent studies with oral vascular endothelial growth factor receptor (VEGFR) inhibitors such as sunitinib, sorafenib and cediranib have shown disease stabilization in patients with advanced synovial sarcoma. Forty-nine percent of patients with synovial sarcoma on the phase II trial of pazopanib had no evidence of disease progression at 12 weeks. The overall impact of chemotherapy on survival has been minimal in advanced soft tissue sarcomas. Anti-VEGF therapies have resulted in improved outcomes for patients with various solid tumors, and have shown preliminary evidence of activity in synovial sarcomas. Combinations of anti-VEGF therapies with agents targeting other pathways dysregulated in sarcomas have the potential to improve the outcome of this difficult-to-treat disease.

References

Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H EdmonsonD R Parkinson
Jan 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G AchenS A Stacker
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J J LewisM F Brennan
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M TrassardJ M Coindre
May 3, 2003·Cancer Cell·Selma PennacchiettiPaolo M Comoglio
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Jan 18, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E L SpurrellI R Judson
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R D'AdamoRobert G Maki
Apr 25, 2006·Nature Reviews. Molecular Cell Biology·Anna-Karin OlssonLena Claesson-Welsh
Nov 3, 2007·Mayo Clinic Proceedings·Keith M Skubitz, David R D'Adamo
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne GeorgeMary L Keohan
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert G MakiGary K Schwartz
Sep 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian I RiniRobert Dreicer
May 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joseph Paul EderPatricia M LoRusso
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth FoxFrank M Balis
Dec 4, 2010·International Journal of Cancer. Journal International Du Cancer·Nicolaus FriedrichsWolfgang Hartmann
May 20, 2011·Nature·Peter Carmeliet, Rakesh K Jain
Dec 1, 2011·Therapeutic Advances in Medical Oncology·J Rafael Sierra, Ming-Sound Tsao

❮ Previous
Next ❯

Citations

May 11, 2013·Current Oncology Reports·Ashley E FrithBrian A Van Tine
Dec 21, 2012·Expert Review of Vaccines·Jordan E BloomBrian M Olson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.